gefitinib has been researched along with Depression in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Buiting, HM; de Kanter, W; Linn, SC; Smorenburg, CH | 1 |
Greer, J; Lynch, TJ; Pirl, WF; Sequist, L; Solis, J; Temel, JS | 1 |
Frantz, S | 1 |
1 review(s) available for gefitinib and Depression
Article | Year |
---|---|
[Living with incurable cancer].
Topics: Aged; Anxiety; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Depression; Emotions; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Psychotherapy; Quality of Life; Quinazolines | 2016 |
2 other study(ies) available for gefitinib and Depression
Article | Year |
---|---|
Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Depression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2009 |
Drug discovery: playing dirty.
Topics: Animals; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Depression; Drug Approval; Drug Design; Drug Evaluation, Preclinical; Drug Industry; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Sensitivity and Specificity; Substrate Specificity; Therapeutics; United States; United States Food and Drug Administration | 2005 |